SAN FRANCISCO, CA USA (UroToday.com) - Complete Title: GU Cancers Symposium 2014 - Session Highlights: Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with mCRPC that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial)
Presented by Robert Dreicer, Robert Jones, Stephane Oudard, Eleni Efstathiou, Fred Saad, Ronald De Wit, Johann Sebastian De Bono, Yuanjun Shi, Bindu Tejura, David B. Agus, Niels Geert Borgstein, Joaquim Bellmunt,and Karim Fizazi at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA
Cleveland Clinic, Cleveland, OH; Institute of Cancer Sciences, Glasgow, United Kingdom; HEGP, Oncologie Médicale, Paris, France; University of Athens Medical School, Athens, TX; University of Montreal Hospital Center, Montreal, QC, Canada; Erasmus MC Cancer Institute, Rotterdam, Netherlands; The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Takeda Pharmaceuticals International Company, Cambridge, MA; Keck School of Medicine of University of Southern California, Beverly Hills, CA; Dana-Farber Cancer Institute, Boston, MA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
Click HERE to read an exclusive report by a UroToday medical writer
Click HERE to read the abstract for this session